LLY vs WFC: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Wells Fargo & Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-01.
Eli Lilly and Company · Healthcare
$934.34
+17.6% upside to fair value
Grade B
High Quality
VS
Wells Fargo & Company · Financial Services
$81.52
+30.6% upside to fair value
Grade B
QuantHub Verdict
WFC has more upside to fair value
(+30.6%).
WFC trades at a lower forward P/E
(11.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
WFC |
| Current Price |
$934.34 |
$81.52 |
| Fair Value Estimate |
$1,098.43 |
$106.48 |
| Upside to Fair Value |
+17.6%
|
+30.6%
|
| Market Cap |
$882.8B |
$250.7B |
| Forward P/E |
33.1x
|
11.9x
|
| EV / EBITDA |
27.9x
|
16.7x
|
| Price / Sales |
12.2x
|
2.0x
|
| Price / FCF |
65.0x
|
-13.2x
|
| Revenue Growth YoY |
+55.5%
|
+7.3%
|
| Gross Margin |
82.7%
|
64.5%
|
| Operating Margin |
46.3%
|
20.5%
|
| Return on Equity |
101.3%
|
12.0%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.54%
|
—
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Eli Lilly and Company is a leading global pharmaceutical firm with a dominant position in the diabetes and obesity markets, driven by its blockbuster GLP-1 drugs Mounjaro and Zepbound which generated $36.5 billion in FY2025. The company reported $65.2 billion in total revenue for 2025, making it the top pharma by revenue globally. It exhibits high business quality with a durable competitive moat …
Wells Fargo & Company is a diversified financial services firm operating primarily in consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. The company benefits from a seasoned CEO with extensive industry experience and has made significant progress in regulatory compliance and operational efficiency, including lifting its asset cap in 2025.…
Accumulation Zones
| Metric |
LLY |
WFC |
| Zone Low |
$823.82 |
$79.86 |
| Zone High |
$933.67 |
$90.51 |
| In Buy Zone? |
No
|
Yes
|